Last updated on February 2015

PankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer


Brief description of study

Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.

Detailed Study Description

The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response after 2nd to 4th line of chemotherapy in patients with epithelial ovarian or fallopian tube or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in a previous line, while the response to the most recent Pt-based chemotherapy must not have lasted more than 12 months. In addition the response between most recent 2 lines of chemotherapy prior start of study medication must not have lasted more than 12 months.

Clinical Study Identifier: NCT01899599

Contact Investigators or Research Sites near you

Start Over

Frank Zimmermann, PhD

Investigator
Rzeszow, Poland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.